Jieling Miao

1.0k total citations
27 papers, 547 citations indexed

About

Jieling Miao is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Jieling Miao has authored 27 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Jieling Miao's work include Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Research Studies (6 papers). Jieling Miao is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (6 papers) and Lung Cancer Research Studies (6 papers). Jieling Miao collaborates with scholars based in United States, Canada and Greece. Jieling Miao's co-authors include Karen Kelly, Mary W. Redman, David R. Gandara, Roy S. Herbst, Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, Philip C. Mack, Charu Aggarwal, Jeffrey D. Bradley and James Moon and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Jieling Miao

27 papers receiving 542 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jieling Miao United States	13	353	300	204	178	47	27	547
Amy Krie United States	5	257 0.7×	172 0.6×	172 0.8×	268 1.5×	80 1.7×	10	527
Rinat Galiulin United States	6	370 1.0×	388 1.3×	135 0.7×	110 0.6×	39 0.8×	7	556
Katherine Minichiello United States	9	389 1.1×	298 1.0×	136 0.7×	121 0.7×	43 0.9×	20	527
Francesca Fenizia Italy	15	327 0.9×	326 1.1×	208 1.0×	401 2.3×	149 3.2×	25	622
Christa G.M. Gadellaa-van Hooijdonk Netherlands	6	349 1.0×	121 0.4×	106 0.5×	141 0.8×	27 0.6×	7	506
Nicole Drezner United States	8	233 0.7×	218 0.7×	160 0.8×	73 0.4×	26 0.6×	13	430
Peter Schirmacher Germany	9	239 0.7×	265 0.9×	143 0.7×	189 1.1×	32 0.7×	17	470
Patricia Gómez Spain	8	486 1.4×	182 0.6×	155 0.8×	257 1.4×	36 0.8×	16	653
Daniel P. Petro United States	11	243 0.7×	194 0.6×	188 0.9×	49 0.3×	40 0.9×	21	428
Bethany Sleckman United States	10	365 1.0×	270 0.9×	201 1.0×	72 0.4×	99 2.1×	19	505

Countries citing papers authored by Jieling Miao

Since Specialization

Citations

This map shows the geographic impact of Jieling Miao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jieling Miao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jieling Miao more than expected).

Fields of papers citing papers by Jieling Miao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jieling Miao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jieling Miao. The network helps show where Jieling Miao may publish in the future.

Co-authorship network of co-authors of Jieling Miao

This figure shows the co-authorship network connecting the top 25 collaborators of Jieling Miao. A scholar is included among the top collaborators of Jieling Miao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jieling Miao. Jieling Miao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Riess, Jonathan W., Jieling Miao, Paul Wheatley‐Price, et al.. (2024). 1309P A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A. Annals of Oncology. 35. S832–S833. 1 indexed citations

Reckamp, Karen L., Mary W. Redman, Konstantin H. Dragnev, et al.. (2024). SWOG S2302, PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS8657–TPS8657. 5 indexed citations

Karim, Nagla Abdel, Jieling Miao, Karen L. Reckamp, et al.. (2024). Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929. Journal of Thoracic Oncology. 20(3). 383–394. 12 indexed citations

Gadgeel, Shirish M., Jieling Miao, Jonathan W. Riess, et al.. (2023). Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042). Clinical Cancer Research. 29(18). 3641–3649. 9 indexed citations

Nanou, Afroditi, Jieling Miao, Frank Coumans, et al.. (2023). Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer. JCO Precision Oncology. 7(7). e2200372–e2200372. 14 indexed citations

Mack, Philip C., Jieling Miao, Mary W. Redman, et al.. (2022). Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403). Clinical Cancer Research. 28(17). 3752–3760. 31 indexed citations

Leighl, Natasha B., Mary W. Redman, Naiyer A. Rizvi, et al.. (2021). Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). Journal for ImmunoTherapy of Cancer. 9(8). e002973–e002973. 38 indexed citations

Argiris, Athanassios, Jieling Miao, Mihaela Cristea, et al.. (2021). A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811). Clinical Lung Cancer. 22(4). 313–323.e1. 17 indexed citations

Paoletti, Costanza, Jieling Miao, Elizabeth P. Darga, et al.. (2019). Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study. Clinical Cancer Research. 25(20). 6089–6097. 57 indexed citations

10.

Edelman, Martin J., Mary W. Redman, Kathy S. Albain, et al.. (2019). SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration–Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). Journal of Thoracic Oncology. 14(10). 1853–1859. 51 indexed citations

11.

Lee, Shing M., et al.. (2019). A comparison of nurses’ and physicians’ perception of cancer treatment burden based on reported adverse events. Health and Quality of Life Outcomes. 17(1). 146–146. 3 indexed citations

12.

Aggarwal, Charu, Mary W. Redman, Primo N. Lara, et al.. (2019). SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). Journal of Thoracic Oncology. 14(10). 1847–1852. 67 indexed citations

13.

Langer, Corey J., Mary W. Redman, James L. Wade, et al.. (2019). SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). Journal of Thoracic Oncology. 14(10). 1839–1846. 58 indexed citations

14.

Miao, Jieling, Mark M. Schubert, Alexander Paterson, et al.. (2019). Factors associated with osteonecrosis of the jaw in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG 0307 trial.. Journal of Clinical Oncology. 37(15_suppl). 552–552. 1 indexed citations

15.

Gadgeel, Shirish M., Jieling Miao, Jonathan W. Riess, et al.. (2019). S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 37(15_suppl). 9021–9021. 12 indexed citations

16.

Miao, Jieling, A. Stopeck, Paul Thompson, et al.. (2019). Abstract P1-17-03: Statin use, site of recurrence, and survival among post-menopausal women taking bisphosphonates as adjuvant therapy for breast cancer (SWOG S0307). Cancer Research. 79(4_Supplement). P1–17. 1 indexed citations

17.

Goldberg, Sarah B., Mary W. Redman, Rogério Lilenbaum, et al.. (2018). OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403. Journal of Thoracic Oncology. 13(10). S343–S344. 5 indexed citations

18.

Tsao, Anne S., Jieling Miao, Ignacio I. Wistuba, et al.. (2018). SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma.. Journal of Clinical Oncology. 36(15_suppl). 8514–8514. 4 indexed citations

19.

Goldberg, Sarah B., James Moon, Rogério Lilenbaum, et al.. (2017). P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403. Journal of Thoracic Oncology. 12(1). S1220–S1221. 1 indexed citations

20.

West, Howard, James Moon, Antoinette J. Wozniak, et al.. (2017). Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non–Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clinical Lung Cancer. 19(1). 84–92. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact